Jupiter Asset Management Ltd. Lowers Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Jupiter Asset Management Ltd. reduced its position in Twist Bioscience Co. (NASDAQ:TWST) by 28.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,801 shares of the company’s stock after selling 6,933 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Twist Bioscience were worth $877,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TWST. Artisan Partners Limited Partnership raised its stake in shares of Twist Bioscience by 111.3% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after acquiring an additional 1,961,621 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company’s stock valued at $15,187,000 after purchasing an additional 300,891 shares during the last quarter. Norges Bank purchased a new position in Twist Bioscience in the 4th quarter worth $10,766,000. Dimensional Fund Advisors LP lifted its stake in Twist Bioscience by 29.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after purchasing an additional 284,884 shares during the last quarter. Finally, Baillie Gifford & Co. boosted its position in Twist Bioscience by 12.1% during the first quarter. Baillie Gifford & Co. now owns 1,227,528 shares of the company’s stock valued at $42,116,000 after buying an additional 132,770 shares during the period.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 5,139 shares of the stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $205,200.27. Following the completion of the transaction, the chief executive officer now owns 499,593 shares of the company’s stock, valued at approximately $19,948,748.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Twist Bioscience news, CEO Emily M. Leproust sold 5,139 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $205,200.27. Following the completion of the transaction, the chief executive officer now owns 499,593 shares in the company, valued at $19,948,748.49. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,114 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $48.00, for a total value of $53,472.00. Following the transaction, the chief executive officer now directly owns 504,732 shares of the company’s stock, valued at approximately $24,227,136. The disclosure for this sale can be found here. In the last three months, insiders have sold 17,388 shares of company stock valued at $776,599. 3.92% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on TWST shares. TD Cowen lifted their price objective on Twist Bioscience from $55.00 to $65.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. The Goldman Sachs Group boosted their price objective on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Robert W. Baird raised their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an “outperform” rating in a report on Monday, August 5th. Barclays lowered their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 5th. Finally, Guggenheim assumed coverage on shares of Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Stock Up 5.3 %

Shares of TWST stock opened at $46.95 on Friday. The stock has a fifty day moving average of $47.71 and a 200 day moving average of $42.70. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -13.97 and a beta of 1.76. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The company had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period in the prior year, the business posted ($1.01) earnings per share. The company’s revenue for the quarter was up 27.7% on a year-over-year basis. Equities research analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.